Clinical Scorecard: Rechallenge with Ruxolitinib Following BRAF/MEK Inhibitor-Induced HLH-Like Hyperinflammatory Syndrome in a Patient with BRAF V600E-Mutated Lung Adenocarcinoma: A Case Study

At a Glance

Key Highlights

• HLH-like hyperinflammatory syndrome is a rare but serious immune-mediated toxicity of BRAF/MEK inhibitors.
• Ruxolitinib, a JAK1/2 inhibitor, can be safely co-administered with dabrafenib and trametinib to manage HLH-like syndrome.
• Steroid-sparing strategies including ruxolitinib enable sustained control of both HLH-like syndrome and lung adenocarcinoma.

Guideline-Based Recommendations

Diagnosis

• Consider HLH diagnosis based on clinical symptoms, hyperferritinemia, and inflammatory markers even if full HLH-2004 criteria are not met.
• Use HLH-2004 criteria as a diagnostic framework requiring at least five of eight criteria for classical HLH.

Management

• Hold BRAF/MEK inhibitors and initiate corticosteroids (e.g., dexamethasone) for initial control of HLH-like syndrome.
• Rechallenge with reduced doses of dabrafenib and trametinib after symptom improvement.
• Introduce ruxolitinib as a steroid-sparing agent to manage HLH-like hyperinflammation while continuing targeted therapy.

Monitoring & Follow-up

• Regularly monitor inflammatory markers including ferritin and C-reactive protein (CRP).
• Assess clinical symptoms such as fatigue, fever, and performance status changes.
• Adjust therapy based on recurrence of symptoms and inflammatory marker trends.

Risks

• Potential for life-threatening hyperinflammatory syndrome induced by targeted therapies.
• Risk of symptom recurrence upon rechallenge with BRAF/MEK inhibitors requiring close monitoring.
• Need for balancing immunosuppression to control HLH-like syndrome without compromising cancer therapy.

Patient & Prescribing Data

Elderly patient with metastatic BRAF V600E-mutated lung adenocarcinoma experiencing HLH-like syndrome after targeted therapy

Initial corticosteroid therapy improved symptoms; ruxolitinib enabled continuation of dabrafenib and trametinib with sustained control of both HLH-like syndrome and cancer.

Clinical Best Practices

• Prompt recognition and treatment of HLH-like hyperinflammatory syndrome in patients on BRAF/MEK inhibitors.
• Use corticosteroids as first-line therapy for HLH-like symptoms.
• Employ ruxolitinib as a steroid-sparing agent to maintain targeted therapy and control inflammation.
• Careful dose adjustments and monitoring to balance efficacy and toxicity.
• Multidisciplinary approach involving oncology and immunology specialists.

References

• HLH-2004 Diagnostic Guidelines